Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. - Wikidata - wikimedia - TriplyDB

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.

http://www.wikidata.org/entity/Q33936179

about

Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy Circulating glioma biomarkers Defects in mitochondrial metabolism and cancer IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Molecular profiling of biliary tract cancer: a target rich disease Oncometabolites: tailoring our genes Role of mitochondrial dysfunction in cancer progression Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.TET proteins and 5-methylcytosine oxidation in hematological cancers Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphoma Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma Circulating Metabolites and Survival Among Patients With Pancreatic Cancer Oncometabolite d-2-hydroxyglutarate impairs α-ketoglutarate dehydrogenase and contractile function in rodent heart.Metabostemness: a new cancer hallmark.Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours Emerging circulating biomarkers in glioblastoma: promises and challenges.New Horizons for Precision Medicine in Biliary Tract Cancers.IDH mutations in cancer and progress toward development of targeted therapeutics.Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Preface to the column "Metabolism of Childhood Cancer".Isocitrate Dehydrogenase Genes.Urine 2-Hydroxyglutarate in Glioma.Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies.Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression Itaconic acid indicates cellular but not systemic immune system activation

P2860

Q26751655-B168D5B0-4DF7-406D-A0BF-8B1F353B6696 Q26830329-7A903A46-E014-4571-9176-40B09E217038 Q27694117-B6F4F0D8-28E8-4BB1-A81D-7B8E868A0BFD Q28066926-4A8AE232-8FAD-4293-B61C-156856044EA1 Q28072275-F7CD7AC2-F421-4039-AC29-1DF356FE5DBC Q28085392-42B9C091-53CA-4730-8AD6-4529920FD25F Q28829644-01D37D63-C1E5-4ED9-9146-D8650829F4CF Q33757122-F04AD069-BED6-433E-B832-51493FF44A73 Q35586677-45720245-E5C2-4851-80E5-C2BC9BAC2C14 Q35745025-9C7C2619-BF8D-465C-A4C8-B28F95DD74EC Q36064917-F42FBBD3-CFB9-4C1D-B7EF-0806C7FB5454 Q36197509-AC4BAE62-5EB5-45F3-8FF6-80F92502C8C2 Q36262067-9FCAADEA-467F-46DB-AD60-998BCF5B3F23 Q36558431-DACB34D8-EA34-4947-96DD-D3AD5C551619 Q36848069-F8400EA0-E057-4F98-83A2-B119C8F716F4 Q37264113-D7A8991A-3CB0-45C2-B65B-A1A16DFEE0A7 Q38261030-7A686AEF-4044-40FE-8326-46D02251FBED Q38375735-8372FB47-7209-4DDA-9A24-96777BF6AD2A Q38591062-4F886DDD-C82E-4767-9281-08B3E197F502 Q38619219-D79339A9-3587-4DEF-8637-7E5C5CCC1BD2 Q38785528-388D30C2-486D-40B5-BD8E-041D7B3F5CA2 Q41026412-A8D4FA1D-61D9-4CD1-BF1D-8F359472A6AE Q41811936-B120426E-87A8-449E-9200-38FEBBFCED57 Q42342897-6D083EF1-EE89-4E5D-8121-453B3DE98E98 Q42369973-1FCEBA2C-68B6-4E51-8EE6-90F1E7CBABD2 Q50033966-ACEC00BE-D904-4326-AFFA-EEBAA0FB74C9 Q55457298-DBC3E423-9749-45A5-AB63-79A022776D0F Q58731797-CD4C0C1E-AADA-4866-A295-9B34BE5763D3 Q58780445-04A8BA33-305E-47E3-99D2-4669BF73D250

P2860

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.

http://www.wikidata.org/entity/Q33936179

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Circulating oncometabolite 2-h ...... trahepatic cholangiocarcinoma.

@ast

Circulating oncometabolite 2-h ...... trahepatic cholangiocarcinoma.

@en

type

label

Circulating oncometabolite 2-h ...... trahepatic cholangiocarcinoma.

@ast

Circulating oncometabolite 2-h ...... trahepatic cholangiocarcinoma.

@en

prefLabel

Circulating oncometabolite 2-h ...... trahepatic cholangiocarcinoma.

@ast

Circulating oncometabolite 2-h ...... trahepatic cholangiocarcinoma.

@en

P1433

Q33936179-18083858-A2FD-4C80-A2E5-80BCF637F7CF

P1476

Q33936179-DCDC4076-49AF-4C07-B21B-AE104F19D9FB

P2093

Q33936179-004D71C7-7CCA-4296-B2E8-CFF2C3BB356D

Q33936179-02C4994A-EDE7-427F-AE86-81129F91AB05

Q33936179-09D6CA74-9656-472D-B275-85DEC83F6304

Q33936179-0A7E47A7-F55D-48E5-A5EF-7800A04F2E13

Q33936179-0EE7C088-5716-4573-8906-DABC4B7E9284

Q33936179-1A197D5D-9E0F-43CC-AE7C-994DD695B46E

Q33936179-1A982AF8-442A-4E06-9F6F-DFBCA8F870B2

Q33936179-1CCE258F-9214-49D7-B3E8-7802507F8D30

Q33936179-1D5CC662-00B2-45B5-A6D5-305B02CE1AD6

Q33936179-419C5D97-393A-4FDB-9358-A6F61A40DFBF

P2860

Q33936179-0345716E-EF24-44F7-9706-1951580EE15D

Q33936179-0351AB0C-A8C5-4AD6-9ADC-EE898C0E9478

Q33936179-06F8140E-E9B4-4223-B9C7-555E21890BB0

Q33936179-09E37A76-BD7F-401B-9889-F390A04357B7

Q33936179-0DE0C8BA-3E82-4040-858B-9716698119A0

Q33936179-14FEC9FC-E9A7-4D1E-9836-8D9FA055E328

Q33936179-3D5920ED-8077-4DFD-88BC-45D3D5D75023

Q33936179-457B897A-97BF-47D8-9524-B829D8F3D94D

Q33936179-48ADECD4-BDA0-4B1C-87A5-D3296196DDE1

Q33936179-4B4415DA-D159-4A9B-9E17-528B3701D8C6

P304

Q33936179-50F1456D-C8FD-43E8-87EA-7FC05604FCA6

P31

Q33936179-EF6D0F6B-5205-4FA2-BC8C-6B40CCF770C8

P356

Q33936179-0815C90D-B6F4-4428-8798-FE8FB8420969

P407

Q33936179-4608F664-08F2-4336-846F-3704B4455988

P433

Q33936179-86E64B4B-8582-4D11-ACA5-5C2B1C8F086B

P478

Q33936179-E038EAD0-1934-459B-8372-E278AC77C901

P50

Q33936179-7CE314DB-DE00-493C-B4F9-F736D7AB04BE

P577

Q33936179-27FE8041-3989-4250-9C87-A3126F9D7D65

P5875

Q33936179-200B29C0-F723-4D58-B490-DA131D39385A

P698

Q33936179-8870D673-C043-48EF-AA48-A683E293FFC2

P921

Q33936179-0232ACCB-5310-4E3A-86E3-E92B207B0748

Q33936179-5ADB5C4B-F661-4A6F-88C1-D90E709A0E9B

P932

Q33936179-645EA06D-4307-4E5A-98E1-047B899A75F5

P356

1078-0432.CCR-13-2649

P1433

Clinical Cancer Research

P1476

Circulating oncometabolite 2-h ...... trahepatic cholangiocarcinoma.

@en

P2093

A John Iafrate

http://www.w3.org/2001/XMLSchema#string

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

Cristina R Ferrone

http://www.w3.org/2001/XMLSchema#string

Darrell R Borger

http://www.w3.org/2001/XMLSchema#string

David C Christiani

http://www.w3.org/2001/XMLSchema#string

David P Ryan

http://www.w3.org/2001/XMLSchema#string

David P Schenkein

http://www.w3.org/2001/XMLSchema#string

Eunice L Kwak

http://www.w3.org/2001/XMLSchema#string

Hannah M Liebman

http://www.w3.org/2001/XMLSchema#string

Hua Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

IDH mutation impairs histone demethylation and results in a block to cell differentiation

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

P304

1884-1890

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-2649

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Nabeel Bardeesy

P577

2014-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259985802

http://www.w3.org/2001/XMLSchema#string

P698

24478380

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma

P932

4107454

http://www.w3.org/2001/XMLSchema#string